Celastrol inhibits polyglutamine aggregation and toxicity though induction of the heat shock response

Yu Qian Zhang; Kevin D. Sarge

doi:10.1007/s00109-007-0251-9

Celastrol inhibits polyglutamine aggregation and toxicity though induction of the heat shock response

Yu Qian Zhang, Kevin D. Sarge

Molecular and Cellular Biochemistry

Research output: Contribution to journal › Article › peer-review

97 Scopus citations

Abstract

Heat shock proteins (hsps) are protective against the harmful effects of mutant expanded polyglutamine repeat proteins that occur in diseases such as Huntington's, prompting the search for pharmacologic compounds that increase hsp expression in cells as potential treatments for this and related diseases. In this paper, we show that celastrol, a compound recently shown to up-regulate hsp gene expression, significantly decreases killing of cells expressing mutant polyglutamine protein. This effect requires the presence of the transcription factor responsible for mediating inducible hsp gene expression, HSF1, and is correlated with decreased amounts and increased sodium dodecyl sulfate (SDS) solubility of polyglutamine aggregates. These results suggest the potential of celastrol as a therapeutic agent in the treatment of human polyglutamine expansion diseases.

Original language	English
Pages (from-to)	1421-1428
Number of pages	8
Journal	Journal of Molecular Medicine
Volume	85
Issue number	12
DOIs	https://doi.org/10.1007/s00109-007-0251-9
State	Published - Dec 2007

Bibliographical note

Funding Information:
Acknowledgements We would like to thank Dr. James Burke for providing polyglutamine-YFP plasmid constructs, Dr. Ivor Benjamin for providing the HSF1+/+ and HSF1−/− MEF cells, and Dr. Doug Andres for providing PC12 cells. We also thank the other members of our laboratory for insightful discussions during the course of this work. This work was supported by NIH grants GM61053 and GM64606 to K.D.S.

Funding

Acknowledgements We would like to thank Dr. James Burke for providing polyglutamine-YFP plasmid constructs, Dr. Ivor Benjamin for providing the HSF1+/+ and HSF1−/− MEF cells, and Dr. Doug Andres for providing PC12 cells. We also thank the other members of our laboratory for insightful discussions during the course of this work. This work was supported by NIH grants GM61053 and GM64606 to K.D.S.

Funders	Funder number
National Institutes of Health (NIH)	GM64606
National Institute of General Medical Sciences	R01GM061053

Keywords

Aggregates
Celastrol
HSF1
Heat shock proteins
Polyglutamine
hsp70

ASJC Scopus subject areas

Molecular Medicine
Drug Discovery
Genetics(clinical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00109-007-0251-9

Cite this

@article{4f02757bb1ed4c80880396330e7d8e42,

title = "Celastrol inhibits polyglutamine aggregation and toxicity though induction of the heat shock response",

abstract = "Heat shock proteins (hsps) are protective against the harmful effects of mutant expanded polyglutamine repeat proteins that occur in diseases such as Huntington's, prompting the search for pharmacologic compounds that increase hsp expression in cells as potential treatments for this and related diseases. In this paper, we show that celastrol, a compound recently shown to up-regulate hsp gene expression, significantly decreases killing of cells expressing mutant polyglutamine protein. This effect requires the presence of the transcription factor responsible for mediating inducible hsp gene expression, HSF1, and is correlated with decreased amounts and increased sodium dodecyl sulfate (SDS) solubility of polyglutamine aggregates. These results suggest the potential of celastrol as a therapeutic agent in the treatment of human polyglutamine expansion diseases.",

keywords = "Aggregates, Celastrol, HSF1, Heat shock proteins, Polyglutamine, hsp70",

author = "Zhang, {Yu Qian} and Sarge, {Kevin D.}",

note = "Funding Information: Acknowledgements We would like to thank Dr. James Burke for providing polyglutamine-YFP plasmid constructs, Dr. Ivor Benjamin for providing the HSF1+/+ and HSF1−/− MEF cells, and Dr. Doug Andres for providing PC12 cells. We also thank the other members of our laboratory for insightful discussions during the course of this work. This work was supported by NIH grants GM61053 and GM64606 to K.D.S.",

year = "2007",

month = dec,

doi = "10.1007/s00109-007-0251-9",

language = "English",

volume = "85",

pages = "1421--1428",

number = "12",

}

TY - JOUR

T1 - Celastrol inhibits polyglutamine aggregation and toxicity though induction of the heat shock response

AU - Zhang, Yu Qian

AU - Sarge, Kevin D.

N1 - Funding Information: Acknowledgements We would like to thank Dr. James Burke for providing polyglutamine-YFP plasmid constructs, Dr. Ivor Benjamin for providing the HSF1+/+ and HSF1−/− MEF cells, and Dr. Doug Andres for providing PC12 cells. We also thank the other members of our laboratory for insightful discussions during the course of this work. This work was supported by NIH grants GM61053 and GM64606 to K.D.S.

PY - 2007/12

Y1 - 2007/12

N2 - Heat shock proteins (hsps) are protective against the harmful effects of mutant expanded polyglutamine repeat proteins that occur in diseases such as Huntington's, prompting the search for pharmacologic compounds that increase hsp expression in cells as potential treatments for this and related diseases. In this paper, we show that celastrol, a compound recently shown to up-regulate hsp gene expression, significantly decreases killing of cells expressing mutant polyglutamine protein. This effect requires the presence of the transcription factor responsible for mediating inducible hsp gene expression, HSF1, and is correlated with decreased amounts and increased sodium dodecyl sulfate (SDS) solubility of polyglutamine aggregates. These results suggest the potential of celastrol as a therapeutic agent in the treatment of human polyglutamine expansion diseases.

AB - Heat shock proteins (hsps) are protective against the harmful effects of mutant expanded polyglutamine repeat proteins that occur in diseases such as Huntington's, prompting the search for pharmacologic compounds that increase hsp expression in cells as potential treatments for this and related diseases. In this paper, we show that celastrol, a compound recently shown to up-regulate hsp gene expression, significantly decreases killing of cells expressing mutant polyglutamine protein. This effect requires the presence of the transcription factor responsible for mediating inducible hsp gene expression, HSF1, and is correlated with decreased amounts and increased sodium dodecyl sulfate (SDS) solubility of polyglutamine aggregates. These results suggest the potential of celastrol as a therapeutic agent in the treatment of human polyglutamine expansion diseases.

KW - Aggregates

KW - Celastrol

KW - HSF1

KW - Heat shock proteins

KW - Polyglutamine

KW - hsp70

UR - http://www.scopus.com/inward/record.url?scp=36849044616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36849044616&partnerID=8YFLogxK

U2 - 10.1007/s00109-007-0251-9

DO - 10.1007/s00109-007-0251-9

M3 - Article

C2 - 17943263

AN - SCOPUS:36849044616

SN - 0946-2716

VL - 85

SP - 1421

EP - 1428

JO - Journal of Molecular Medicine

JF - Journal of Molecular Medicine

IS - 12

ER -

Celastrol inhibits polyglutamine aggregation and toxicity though induction of the heat shock response

Abstract

Bibliographical note

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this